SynAct Pharma (SYNACT) investor relations material

Company overview and team

• Focuses on inflammation therapies, with a 12-year history and roots in a successful pharma spin-out.

• Holds strong IP extending to 2042, with potential U.S. extension.

• Operates with a small, experienced team and an active board with notable industry backgrounds.

• Well-financed through Q3 2027, with 45% insider ownership and a SEK 1 billion market cap.

Pipeline and clinical progress

• Lead asset targets rheumatoid arthritis (RA), aiming to delay use of JAK inhibitors and TNF blockers.

• Phase II-b RA data published; preparing for phase III and ongoing partnering discussions.

• Two additional phase II programs in dengue and influenza are actively recruiting in Brazil and New Zealand, respectively.

• Dengue study in Brazil includes a 50/50 cost-sharing partnership with a major local pharma company.

Market positioning and differentiation

• RA market in the U.S. includes 1.8 million patients, with 90,000 new potential users annually.

• Compound is positioned as an add-on to methotrexate, aiming to delay progression to more side-effect-prone therapies.

• Demonstrates efficacy comparable to JAK inhibitors without immune suppression or major side effects.

• Acute inflammation indications (dengue, influenza) target markets with high patient volumes and strained hospital systems.